Insulin-producing b cells in patients with type 1 diabetes (T1D) are destroyed by T lymphocytes. We investigated whether targeting the T-cell receptor (TCR) with a monoclonal antibody (mAb) abrogates T-cell response against residual and newly formed islets in overtly diabetic nonobese diabetic (NOD) mice. NOD mice with blood glucose levels of 250 to 350 mg/dL or 350 to 450 mg/dL were considered as new-onset or established overt diabetes, respectively. These diabetic NOD mice were transiently treated with an anti-TCR b chain (TCRb) mAb, H57-597, for 5 days. Two weeks later, some NOD mice with established overt diabetes further received hepatic gene therapy using the isletlineage determining gene Neurogenin3 (Ngn3), in combination with the islet growth factor gene betacellulin (Btc). We found that anti-TCRb mAb (50 mg/d) reversed .80% new-onset diabetes in NOD mice for .14 weeks by reducing the number of effector T cells in the pancreas. However, antiTCRb mAb therapy alone reversed only ;20% established overt diabetes in these mice. Among those overtly diabetic NOD mice whose diabetes was resistant to anti-TCRb mAb treatment, ;60% no longer had diabetes when they also received Ngn3-Btc hepatic gene transfer 2 weeks after initial antiTCRb mAb treatment. This combination of Ngn3-Btc gene therapy and anti-TCRb mAb treatment induced the sustained formation of periportal insulin-producing cells in the liver of overtly diabetic mice. Therefore, directly targeting TCRb with a mAb potently reverses new-onset T1D in NOD mice and protects residual and newly formed gene therapy-induced hepatic neo-islets from T-cell-mediated destruction in mice with established overt diabetes. (Endocrinology 158: 3140-3151, 2017) 
I
nsulin replacement is the standard therapy for type 1 diabetes (T1D). Unfortunately, exogenous insulin fails to recapitulate the normal pancreatic insulin dynamics and, despite the best available insulin regimens, individuals with T1D continue to display significantly increased mortality and morbidity. Patients with T1D manifest the disease when the majority of the insulinproducing pancreatic b cells are destroyed by T-cellmediated autoimmunity. In theory, T-cell targeted therapy is the treatment of choice because it addresses the primary defect in T1D and has the potential to restore b-cell survival and function (1) .
A central step to initiate a T-cell response is the engagement of T-cell receptor (TCR) on T cells with antigen-loaded major histocompatibility complex on antigen-presenting cells. In addition, costimulatory and cytokine signals also control T-cell activation (1) . In the context of T1D, efforts have been made to target islet antigens (2) (3) (4) , deplete T cells (5) , alter TCR signaling (1, 6) , block costimulation (7) , and neutralize cytokines (8) .
Nevertheless, much less attention has been paid to the TCR itself as a target of immunotherapy.
We recently investigated the therapeutic effects of a monoclonal antibody (mAb) specific for TCR b chain (TCRb) and showed that transient anti-TCRb mAb treatment induced long-term cardiac allograft survival in fully major histocompatibility complex-mismatched recipient mice as well as reversed new-onset diabetes in nonobese diabetic (NOD) mice (9, 10) . Moreover, antiTCRb mAb also significantly prolonged the survival of transplanted C57BL/6 islets in NOD mice, which exerted not only allogeneic response but also autoimmune response against the transplanted islets (11). Thus, anti-TCRb mAb has strong therapeutic potential for treatment of T1D by abrogating the anti-islet immunity.
Patients with new-onset T1D have been shown to harbor considerable numbers of residual b cells in the pancreas. Potential immunotherapies may, in theory, partly reverse disease in these patients by protecting the residual b cells. By contrast, islet b cells in patients with late-stage T1D have mostly been destroyed. At this stage, pancreas transplantation would restore glycemic and metabolic control much more effectively. However, the limited availability of donor pancreases limits the number of pancreas transplantations that can be performed. Thus, much attention has been devoted lately to replenishing new glucose-responsive b cells, such as replication of residual b cells and generation of new b cells in vitro or in vivo (12) .
We have previously shown that ectopic islet neogenesis in the periportal regions of the liver is achieved by transfer of the islet-lineage determining gene Neurogenin3 (Ngn3), and the islet growth factor gene betacellulin (Btc) (13) . A helper-dependent adenoviral (HDAd) vector was used to deliver the Ngn3 and Btc genes. These de novo generated neo-islets secrete insulin in a glucose-responsive manner to restore glucose control in streptozotocin-induced diabetic B6 mice, but not in NOD mice in which islet-destructive T cells continue to exist (13, 14) . The aim of this study was to determine whether anti-TCRb mAb reverses T1D in NOD mice and protects Ngn3/Btc-induced neogenesis from T-cell-mediated destruction. We believe effective therapies for de novo islet generation in patients with T1D must be supported by a potent immunotherapy that halts T-cell attack.
Research Design and Methods
Mice C57BL/6, NOD, and NOD/scid mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All animal procedures were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine and the Institutional Animal Care and Use Committee at Houston Methodist Research Institute.
Diabetes diagnosis and intervention
Starting from 10 weeks of age, NOD female mice were screened for hyperglycemia three times per week. NOD mice were diagnosed with new-onset diabetes when two consecutive glucose levels were between 250 and 350 mg/dL, and with established overt diabetes when two consecutive glucose levels were between 350 and 450 mg/dL. To reverse new-onset diabetes, newly diagnosed mice were injected intraperitoneally (IP) with an anti-TCRb mAb (clone H57 597; Bio X Cell, West Lebanon, NH), an anti-TCRa mAb (clone H28 710; Santa Cruz Biotechnology, Dallas, TX), or phosphate-buffered saline (PBS) control for 5 consecutive days. To reverse overt diabetes, overtly diabetic NOD mice were treated with 50 mg/d anti-TCRb mAb for 5 consecutive days. If overtly diabetic mice maintained blood glucose levels between 350 and 450 mg/dL at day 14 after initial anti-TCRb mAb treatment, they were treated with 5 3 10 11 vector particles of HDAd-Ngn3 plus 1 3 10 11 HDAd-Btc to further reverse diabetes, or with empty control vectors, as previously described (13) (14) (15) .
Intraperitoneal glucose tolerance test and serum insulin level
Four to 6 weeks after initial anti-TCRb mAb treatment, NOD mice that had been fasted for 4 hours were injected IP with 1.5 g/kg D-glucose. Blood glucose levels were assessed at 0, 15, 30, 60, and 120 minutes after glucose injection. Additional blood samples were obtained at the same time points to determine the serum insulin level, using the Mercodia Ultrasensitive Mouse Insulin ELISA (enzyme-linked immunosorbent assay) kit (Winston-Salem, NC).
Insulitis score, immunohistochemistry, immunofluorescence staining, and pancreatic insulin content Pancreata were harvested at 14 weeks after initial anti-TCRb mAb treatment. Paraffin sections were prepared and stained with hematoxylin and eosin. An insulitis score for each islet was determined as follows: 0, no insulitis; 1, peri-insulitis; 2, intraislet insulitis affecting ,50% of islet area; and 3, intraislet insulitis affecting .50% of islet area. Immunostaining of insulin was performed on paraffin-embedded pancreas and liver sections, as previously described (13, 15) . Immunofluorescence staining of CD4, CD8, and insulin with 4 0 ,6-diamidino-2-phenylindole was performed on frozen sections of pancreas. The staining method has been previously described (13, 15) . For measuring pancreatic insulin content, snap-frozen pancreata were homogenized in precooled acid ethanol overnight. Insulin concentration in supernatants was measured using the aforementioned Mercodia enzyme-linked immunosorbent assay and total protein content was determined with the 2D Quant kit (GE Healthcare, Piscataway, NJ).
Isolation of pancreatic infiltrating lymphocytes and flow cytometric analysis
The pancreas of each killed NOD mouse was perfused with 2 mL of Liberase TL enzyme (1.08 Wünsch units /mL; Roche, Indianapolis, IN) through the common bile duct while the duodenum entry was clamped. The pancreas was removed and incubated in a 37°C water bath for 20 minutes, then washed and pushed through a 40-mm cell strainer to obtain a suspension. Pancreatic infiltrating lymphocytes were then isolated from the suspension using a Lympholyte-M solution (Cedarlane Laboratories, Burlington, NC).
Lymphocytes isolated from the pancreas, spleen, and pancreatic draining lymph nodes (PLNs) were surface stained with various fluorescent antibodies and intracellularly stained with Foxp3 using Mouse Regulatory T-Cell Staining Kit (eBioscience, San Diego, CA). For IFN-g and TNF-a expression, lymphocytes isolated from the pancreas were stimulated for 4 hours with 50 ng/mL phorbol 12-myristate 13-acetate and 500 ng/mL ionomycin (both from Sigma-Aldrich, St. Louis, MO) in the presence of GolgiStop (BD Biosciences, San Diego, CA), and stained with fluorescent antibodies against cytokines using the Cytofix/Cytoperm Solution Kit (BD Biosciences). Flow cytometry analysis was performed using a FACS Canto II analyzer (BD Biosciences).
CD4 and CD8 T-cell numbers in pancreas were calculated by multiplying the total live cell counts isolated from pancreas (TC 20 Automated Cell Counter; Bio-Rad, Hercules, CA) by percentage of CD4 + or CD8 + cells within the Zombie Aqua negative living cells (FACS Canto II analyzer; BD Biosciences).
Skin transplantation
Skin transplantation was performed as described previously (9) . Briefly, ear skin (1.0 cm 2 ) from the donor mice was grafted onto the flank of recipient mice. The graft was covered with a sterile bandage, which was removed on day 6 or 7. A skin graft was considered rejected when 80% of the grafted tissue became necrotic.
Adoptive transfer of diabetes into NOD/scid mice NOD/scid mice were injected intravenously with 1 3 10 7 total or CD25 -splenocytes isolated from anti-TCRb-treated NOD mice (at 14 weeks after initial treatment), or 1 3 10 7 total splenocytes from nondiabetic NOD mice. After adoptive cell transfer, the incidence of diabetes in these NOD/scid mice was monitored by screening for hyperglycemia three times per week.
Statistical analysis
The results of the graft survival data were analyzed by MannWhitney test. Other statistical analysis was performed using an unpaired, two-tailed, Student t test to calculate P values. Calculated P , 0.05 was considered statistically significant.
Results
Anti-TCRb mAb effectively reversed new-onset diabetes in NOD mice NOD mice were diagnosed with new-onset diabetes when two consecutive glucose levels were between 250 and 350 mg/dL. To reverse new-onset diabetes, newly diagnosed NOD mice were injected IP daily with either an anti-TCRa or an anti-TCRb mAb (10 or 50 mg) for 5 consecutive days. New-onset diabetic mice injected IP with PBS served as a control group. Mice were then monitored for blood glucose levels for 14 weeks after treatment (i.e., the duration of the study). The anti-TCRb mAb treatment restored euglycemia in 83.33% (n = 6) of the mice in the high-dose group and 50% (n = 6) among the low-dose group ( Fig. 1a and 1b) . Anti-TCRa mAb, 10 mg/dose ( Fig. 1a and 1b) or 50 mg/dose (data not shown), did not reverse new-onset diabetes, though it marginally delayed the progression of diabetes compared with the PBS group ( Fig. 1a and 1b) . Therefore, antiTCRb mAb potently induces a long-term reversal of newonset diabetes in NOD mice.
Anti-TCRb mAb reduced the severity of insulitis and preserved b-cell mass in NOD mice
To study the effect of anti-TCRb mAb on preserving b-cell function, we performed an intraperitoneal glucose tolerance test (IPGTT; n = 6 per group) 4 to 6 weeks after the initial anti-TCRb treatment. PBS-treated NOD mice with full-blown diabetes (i.e., blood glucose level .600 mg/dL) were used as controls. As shown in the left panel of Fig. 2a , blood glucose levels during IPGTT in PBS-treated NOD mice were markedly higher than that in anti-TCRb-treated groups and nondiabetic NOD mice. Moreover, antiTCRb-treated mice displayed significantly higher serum insulin levels before IPGTT than PBS-treated mice, but they failed to increase insulin secretion in responsive to glucose injection (Fig. 2a, right panel) . We also measured the pancreatic insulin content in anti-TCRb-treated groups at 14 weeks after treatment or in PBS-treated mice with fullblown diabetes. We found that pancreata of antiTCRb-treated mice exhibited a significantly higher insulin concentration than those of PBS-treated NOD mice with full-blown diabetes ( Fig. 2b ; n = 6 per group).
We then performed histochemical and immunofluorescence analyses of pancreata from the anti-TCRbtreated groups at 14 weeks after treatment and PBS-treated NOD mice with full-blown diabetes. AntiTCRb mAb treatment significantly decreased the severity of insulitis in NOD mice compared with PBS treatment (Fig. 2c-2e) . Moreover, the residual islets protected by anti-TCRb mAb treatment displayed easily detectable insulin immunoreactivity (Fig. 2c, lower panels) and a reduction of the CD4 and CD8 T-cell infiltration (Fig. 2e) .
Three groups of NOD mice were used to determine the numbers of pancreas-infiltrating T cells, including NOD mice treated with the 50-mg dose of anti-TCRb mAb at 10 days after initial treatment, nondiabetic NOD mice, and PBS-treated NOD mice exhibiting hyperglycemia. The numbers of pancreas-infiltrating CD4 and CD8 T cells were significantly reduced in anti-TCRb mAbtreated mice than those in PBS-treated NOD mice (Fig.  2f) . Taken together, transient anti-TCRb mAb treatment during new-onset diabetes preserved functional residual islets in pancreata of NOD mice.
Anti-TCRb mAb significantly changed the phenotype of infiltrating T cells in pancreata of NOD mice
Murine naïve T cells highly express L-selectin (also known as CD62L) but not CD44. Upon activation, T cells downregulate CD62L and upregulate CD44 expressions. Herein, to determine how anti-TCRb mAb halts T-cell-mediated islet destruction, we measured CD62L and CD44 expression on T cells from the spleen, PLNs, and pancreas of NOD mice. Three groups of NOD mice were assessed, including anti-TCRb mAbtreated NOD mice at 14 weeks after T1D reversal, nondiabetic NOD mice at 26 to 32 weeks of age, and PBS-treated NOD mice exhibiting hyperglycemia. We found that, in the spleen and PLN, the majority of CD62L -cells were CD44 + in CD4 and CD8 T cells (Fig.  3a, i and ii, top and middle panels), and the frequencies of CD62L -CD44 + cells were similar between groups (Fig. 3b, i and ii, left panels). Anti-TCRb mAb also did not dramatically alter the total T-cell numbers in spleen and PLNs of NOD mice (data not shown). Pancreatic infiltrating CD62L -T cells exhibited a diverse range of CD44 expression. The frequencies of CD62L -cells among CD4 and CD8 pancreatic infiltrating T cells were significantly higher in PBS-treated diabetic mice than those in the nondiabetic and antiTCRb mAb groups (Fig. 3a, i and ii, bottom panels, and 3b, right panels). The frequencies of CD4 + CD25 + Foxp3 + regulatory T (Treg) cells in the second lymphoid organs and pancreata were not significantly different between the three experimental groups (Fig. 3a and 3b, iii) . We further analyzed the expression of activation/ dysfunction markers and cytokine production by pancreatic infiltrating T cells. Three groups of NOD mice were studied, including 50 mg anti-TCRb mAb-treated NOD mice at 10 days after initial treatment, nondiabetic NOD mice, and PBS-treated NOD mice exhibiting hyperglycemia. The percentages of CD69 + and CD28
+ populations in infiltrating CD4 T cells and the percentage of CD28 + population in infiltrating CD8 T cells from the anti-TCRb mAb-treated group were significantly higher than those of the nondiabetic group, but were not significantly different from those of the PBS-treated group (Fig. 3c and 3d ). OX40 expression on infiltrating CD4 T cells from the anti-TCRb mAb-treated group increased significantly than those of the nondiabetic group and the PBS-treated group (Fig. 3e ). CD40L expression was not different between any groups (Fig. 3f) .
Most interestingly, pancreatic infiltrating T cells can be divided into PD-1 + and PD-1 -populations. Most infiltrating T cells from the anti-TCRb mAb group were PD-1 + . The percentages of PD-1 + population in infiltrating CD4 and CD8 T cells from the anti-TCRb mAb group were, indeed, significantly higher than those of the other two groups (Fig. 3g ), but the percentages of IFN-gproducing population in them were significantly lower than those of the PBS-treated group (Fig. 3h) . Taken together, the findings indicate anti-TCRb mAb significantly changes the phenotype of infiltrating T cells in pancreata of diabetic NOD mice.
Anti-TCRb mAb-treated NOD mice were immunocompetent to reject skin allografts and contained diabetogenic cells To determine the immunocompetence of NOD mice after T1D reversal, we transplanted C57BL/6 skin allografts onto NOD mice that had been treated with anti-TCRb mAb 12 weeks before (n = 6). Nondiabetic NOD mice were also transplanted with C57BL/6 skin and used as a control group (n = 6). We found that the C57BL/6 skin allografts were acutely rejected in antiTCRb mAb-treated mice, with a mean (6 standard deviation) survival time of 8 6 1 days, which was not different from that in nondiabetic NOD mice (Fig. 4a) . Hence, NOD mice treated with anti-TCRb mAb remained immunocompetent.
We then used an adoptive transfer model of diabetes to determine whether anti-TCRb mAb selectively eliminated the diabetogenic T cells. Splenocytes were isolated from either anti-TCRb mAb-treated NOD mice at 14 weeks after T1D reversal or nondiabetic NOD mice at 26 to 32 weeks of age, and were adoptively transferred into NOD/scid recipient mice. As shown in Fig. 4b , diabetes was induced in both groups similarly, and all NOD/scid mice became diabetic within 6 weeks after cell transfer. Moreover, we partially depleted Treg cells in the splenocytes of anti-TCRb mAb-treated NOD mice by isolating CD25
-cells (Fig. 4c) . Transfer of those CD25 -splenocytes moderately accelerated T1D onset in NOD/ scid mice (Fig. 4b) . Therefore, diabetogenic T cells were not eliminated in anti-TCRb mAb-treated NOD mice, and their diabetogenic potential might be partially inhibited by Treg cells.
Ngn3-Btc islet-induction gene therapy reversed overt diabetes in NOD mice resistant to anti-TCRb mAb treatment
To further determine the potency of targeting TCR in reversing T1D, 29 NOD mice with established overt diabetes (i.e., blood glucose level of 350 to 450 mg/dL) were treated with 50 mg/d anti-TCRb mAb for 5 consecutive days (Fig. 5a) . Two weeks after the first dose of anti-TCRb mAb, the following 16 mice were left without further treatment. (1) Eight NOD mice responded to antiTCRb mAb alone with decreasing blood glucose level (,350 mg/dL). Six of those eight NOD mice that responded to the anti-TCRb mAb-alone treatment remained diabetes free for at least an additional 12 weeks. (2) Eight NOD mice became severely hyperglycemic (i.e., blood glucose level .450 mg/dL) and developed fullblown diabetes within 2 weeks. The dynamic changes of the blood glucose levels of these 16 mice are shown in the left panel of Fig. 5b . Hence, anti-TCRb mAb therapy reversed only ;20% (six of 29) of established overt diabetes in NOD mice.
As shown in Fig. 5b (left panel, solid lines) , 13 NOD mice maintained blood glucose levels between 350 and 450 mg/dL at 2 weeks after the first dose of anti-TCRb mAb. This relative resistance of overtly diabetic NOD mice to anti-TCRb mAb therapy may be attributed to the severe loss of pancreatic islets. Therefore, we tested the efficacy of supplying these mice with neo-islets by Ngn3-Btc gene therapy using a method that was previously developed by our laboratory (13) (14) (15) . These 13 NOD mice were selected for vector injection at 2 weeks after the first dose of anti-TCRb mAb (Fig. 5b , left panel, short solid lines); eight of them were injected with HDAd vectors encoding Ngn3 and Btc (Fig. 5b , top right panel), whereas five other mice were injected with empty control vectors (Fig. 5b, bottom right  panel) . We found that all animals in the control-vector group developed full-blown diabetes in 8 weeks, whereas five of eight NOD mice in the Ngn3-Btc gene therapy group no longer were diabetic and remained diabetes free during the 14-week study period (Fig. 5b , right panels, and 5c).
We performed IPGTT (n = 5 per group) in three groups of mice at 4 to 6 weeks after initial anti-TCRb mAb treatment: (1) overt diabetes reversed by anti-TCRb mAb alone, (2) overt diabetes reversed by anti-TCRb mAb plus Ngn3-Btc gene transfer, and (3) full-blown diabetes that developed after treatment with anti-TCRb mAb plus control vectors. Blood glucose levels during IPGTT in group 3 were markedly higher than that in groups 1 and 2 (Fig. 6a, upper panel) . Moreover, during IPGTT, serum insulin levels in groups 1 and 2 were also significantly higher than those in group 3, though insulin secretion did not increase in response to glucose injection in all three groups (Fig. 6a, lower panel) . We also monitored the serum insulin level before diabetes onset and at different times after treatment. Both groups 2 and 3 were relatively resistant to anti-TCRb mAb and their serum insulin levels declined dramatically at 2 weeks after initial anti-TCRb mAb treatment. Nevertheless, at 4 weeks after initial antiTCRb mAb treatment (2 weeks after vector injection), the serum insulin levels in group 2 were partially restored after Ngn3-Btc gene transfer, whereas those of group 3 further declined to almost undetectable levels (Fig. 6b) . Figure 6c shows that in the liver of NOD mice treated with anti-TCRb mAb and Ngn3-Btc gene transfer, insulin-expressing cells were present surrounding the portal vein in the liver. In contrast, insulin-expressing cells were never detected in the liver of mice treated with control vectors (Fig. 6c) . Taken together, anti-TCRb mAb combined with Ngn3-Btc gene transfer reversed established overt diabetes in NOD mice.
Discussion
In this study, we investigated the efficacy of an anti-TCRb mAb plus Ngn3-Btc gene transfer in reversing T1D. We found that a 5-day course of 50 mg of anti-TCRb mAb reversed .80% of new-onset T1D in NOD mice. Even in overtly diabetic NOD mice that were relatively resistant to anti-TCRb mAb alone, we successfully reversed the diabetes in ;60% of these mice by treating them with a combination of anti-TCRb mAb and Ngn3-Btc gene transfer. Importantly, the enduring T1D reversal observed in this autoimmune diabetes mouse model was associated with a competent immune system as well as partial restoration of insulin production.
Human patients and NOD mice with new-onset T1D retain considerable numbers of residual pancreatic islets. The survival of these residual islets is being heavily challenged: Diabetogenic T cells are actively engaged in their destruction. An ultimate goal of T1D immunologists would be to halt islet destruction by selectively eliminating or disarming diabetogenic T cells while leaving other immune system components intact (16) . However, the molecular mechanism of T-cell-mediated islet destruction remains unclear, and thus the optimal targets for T1D immunotherapy are poorly defined (1). To date, nonspecific immune suppressants, such as anti-CD3 mAb and antithymocyte globulin, are still the most potent immunotherapies to abrogate anti-islet T-cell responses (1, 4) . We have recently demonstrated the potency of an anti-TCRb mAb in inducing long-term transplant survival (9, 11, 17) and reversing new-onset T1D in mice (10) . The same anti-TCRb mAb clone has also been shown to be effective in preventing experimental autoimmune encephalomyelitis and collageninduced arthritis in animal models (18, 19) . Herein, we demonstrated that anti-TCRb mAb preserved neurogenin3-induced neo-islets and reversed overt T1D in NOD mice.
The anti-TCRb mAb treatment was transient but its effect on reversal of new-onset T1D was lasting. Moreover, anti-TCRb mAb-treated NOD mice were immune competent to reject allogeneic skin grafts. Hence, tolerogenic mechanisms may be invoked by anti-TCRb mAb to selectively abrogate anti-islet autoimmunity. Multiple mechanisms exist to induce tolerance in peripheral T cells, including functional anergy (20) , peripheral deletion by apoptosis (21), clonal exhaustion (22) , and suppression by Treg cells (23) . In our adoptive transfer study, total splenocytes from T1D-reversed NOD mice robustly transferred diabetes in NOD/scid recipients, and partially depleting Treg cells in the splenocytes before transfer moderately accelerated T1D onset. Thus, diabetogenic T cells are not eliminated in T1D-reversed NOD mice and their function is partially suppressed by Treg cells. Interestingly, 40% to 65% of pancreatic infiltrating T cells in anti-TCRb mAb-treated NOD mice expressed a naïve cell marker CD62L. In general, CD62L facilitates naïve T cells homing to lymphoid tissues (24) and is not required for diabetes onset and islet infiltration of T cells (25) . More importantly, we previously showed that the anti-TCRb mAb treatment increased T-cell expression of PD-1 in diabetic NOD mice (10) . Herein, we further found pancreatic infiltrating T cells can be divided into PD-1 + and PD-1 -populations. The majority of pancreatic infiltrating T cells in the anti-TCRb mAb group were PD-1 + , which is associated with low IFN-g production. Hence, antiTCRb mAb induces an exhaustion-like phenotype of T cells. In future studies, we would like to determine whether T-cell exhaustion or dysfunction can be induced in T1D by anti-TCRb mAb, and whether induction of T-cell exhaustion is a potential approach for treating T1D. NOD mice with overt diabetes are resistant to antiTCRb mAb, which may be simply attributed to the severe loss of functional islets. To test this notion, Ngn3-Btc genes were transferred into overtly diabetic NOD mice that had maintained blood glucose levels between 350 and 450 mg/dL for 2 weeks after antiTCRb mAb treatment. Five of eight Ngn3-Btc genetransferred NOD mice successfully reversed disease and remained diabetes free for at least 14 weeks. In the liver of these diabetes-reversed mice, insulin-expressing cells were detected surrounding the portal vein. Therefore, anti-TCRb mAb combined with Ngn3-Btc gene transfer potently reversed overt T1D by inducing and protecting islet neogenesis.
In summary, anti-TCRb mAb induced an enduring reversal of new-onset or overt diabetes in NOD mice when used alone or combined with Ngn3-Btc transfer, respectively. Many efforts have been made to induce islet expansion or neogenesis (12) . A potent immunotherapy must also be developed as a prerequisite for successful islet neogenesis. We suggest adding antiTCRb mAb to the limited list of T1D immunotherapies that effectively protect residual and newly formed islets.
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